- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 19.02. | enGene Holdings Inc. - 10-K/A, Annual Report | 1 | SEC Filings | ||
| 30.01. | Jefferies startet Coverage für Engene mit 'Buy' und sieht 173 % Kurspotenzial | 4 | Investing.com Deutsch | ||
| 30.01. | Jefferies initiates coverage on Engene stock with Buy rating | 1 | Investing.com | ||
| ENGENE HOLDINGS Aktie jetzt für 0€ handeln | |||||
| 23.01. | enGene extends momentum with another 14% surge on Friday | 2 | Seeking Alpha | ||
| 21.01. | enGene Holdings Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 23.12.25 | Engene stock remains a Buy at H.C. Wainwright on NMIBC treatment advantages | 4 | Investing.com | ||
| 22.12.25 | enGene completes enrollment in bladder cancer treatment trial | 2 | Investing.com | ||
| 22.12.25 | Blasenkrebs-Studie: enGene übertrifft Rekrutierungsziel | 2 | Investing.com Deutsch | ||
| 22.12.25 | enGene Holdings GAAP EPS of $2.29 | 1 | Seeking Alpha | ||
| 22.12.25 | enGene Holdings Inc. - 10-K, Annual Report | - | SEC Filings | ||
| 22.12.25 | enGene Holdings Inc. - 8-K, Current Report | - | SEC Filings | ||
| 03.12.25 | H.C. Wainwright maintains Buy rating on Engene stock as detalimogene joins FDA pilot program | 3 | Investing.com | ||
| 02.12.25 | FDA-Förderprogramm für Blasenkrebstherapie treibt enGene-Aktie an | 1 | Investing.com Deutsch | ||
| 02.12.25 | FDA selects enGene's bladder cancer therapy for development program | 3 | Investing.com | ||
| 13.11.25 | enGene prices $130 million public offering of shares and warrants | 2 | Investing.com | ||
| 13.11.25 | enGene platziert Aktien und Optionsscheine im Wert von 130 Millionen US-Dollar | 3 | Investing.com Deutsch | ||
| 12.11.25 | enGene announces proposed public offering | 6 | Seeking Alpha | ||
| 12.11.25 | Engene stock price target raised to $33 by Oppenheimer on strong trial data | 2 | Investing.com | ||
| 12.11.25 | Leerink Partners raises Engene stock price target to $21 on LEGEND data | 1 | Investing.com | ||
| 12.11.25 | Leerink Partners raises Engene stock price target to $21 on promising trial data | 2 | Investing.com |
1 2 3 Weiter >>
45 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 92,30 | +0,27 % | BioNTech Aktie: Die Wende naht! Golden Cross! | © Foto: 2026 BioNTech SE. Alle Recht vorbehalten.Fast wie in der Serie "Game of Thrones", wo der Winter naht, könnte bei BioNTech die Wende nahen. Nach dem Kursrausch in der Corona-Ära folgte der brutale... ► Artikel lesen | |
| AMGEN | 329,30 | -0,18 % | AAPL, AA, BKR, and AMGN are among the top stocks for momentum, says Oppenheimer | ||
| NOVAVAX | 8,765 | +1,40 % | FOMO an der Wall Street: Novavax meldet überraschenden Gewinn - Aktie schießt zweistellig hoch | © Foto: picture alliance / Ulrich Baumgarten | Ulrich BaumgartenEin Ergebnis, das niemand erwartet hatte, gepaart mit neuen Big-Pharma-Deals: Novavax sorgt für FOMO an der Wall Street. Wie lange hält... ► Artikel lesen | |
| BIOGEN | 161,20 | +0,19 % | WONBIOGEN Co., Ltd: Won BioGen Accelerates Global Market Expansion with Advanced Moist Wound Care Technology | SEOUL, South Korea, Feb. 24, 2026 /PRNewswire/ -- Medical device manufacturer Won BioGen (CEO Kim Won-il) is accelerating its global market expansion based on its advanced moist wound care... ► Artikel lesen | |
| VIKING THERAPEUTICS | 28,845 | +1,16 % | Viking Therapeutics: The High-Stakes Weight Loss Contender | ||
| MAINZ BIOMED | 0,767 | +1,71 % | Mainz BioMed NV: Mainz Biomed to Present at the Pancreatic Cancer Session at Digestive Disease Week, Demonstrating Effectiveness of mRNA Biomarkers in Blood Samples | ||
| INTELLIA THERAPEUTICS | 13,110 | -0,87 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM | CAMBRIDGE, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing... ► Artikel lesen | |
| TEMPUS AI | 44,800 | -1,75 % | Tempus AI Quartalszahlen: 90 % Umsatzplus bestätigen KI-Trend in der Medizin | CHICAGO, Illinois (IT-Times) - Das Diagnose-Technologie-Unternehmen Tempus AI hat seine Ergebnisse für das vierte Quartal 2025 veröffentlicht und ein rasantes Umsatzwachstum verzeichnet. Tempus AI -... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 7,426 | +0,76 % | BioCryst Pharmaceuticals, Inc.: BioCryst Reports Full Year 2025 Financial Results and Provides Business Update | -Full year 2025 ORLADEYO® net revenue of $601.8 million (+38% y-o-y; +43% y-o-y excluding European ORLADEYO revenue following the sale of the European ORLADEYO business to Neopharmed Gentili S.p.A.... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 51,62 | +0,98 % | FDA Expands BioMarin's PALYNZIQ Approval To Include Pediatric PKU Patients Ages 12 And Up | WASHINGTON (dpa-AFX) - BioMarin Pharmaceutical Inc. (BMRN) announced Friday that the U.S. Food and Drug Administration has approved the company's supplemental Biologics License Application for... ► Artikel lesen | |
| EXELIXIS | 34,820 | -0,80 % | Forecasting The Future: 11 Analyst Projections For Exelixis | ||
| SAREPTA THERAPEUTICS | 14,000 | +0,32 % | Sarepta Therapeutics, Inc. - 10-K, Annual Report | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,436 | +3,32 % | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. - S-8, Securities to be offered to employees in employee benefit plans | ||
| CARDIOL THERAPEUTICS | 0,860 | -0,81 % | Cardiol Therapeutics Inc.: Cardiol Therapeutics to Present at TD Cowen 46th Annual Health Care Conference | Toronto, Ontario--(Newsfile Corp. - February 25, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing... ► Artikel lesen | |
| VAXART | 0,510 | 0,00 % | Vaxart, Inc.: Vaxart Provides Business Update and Reports Third Quarter 2025 Financial Results | Entered into an exclusive license agreement with Dynavax for the Company's COVID-19 oral pill vaccine candidate for potential cumulative proceeds of up to $700 million plus royalties Completed enrollment... ► Artikel lesen |
Das Unternehmen ENGENE HOLDINGS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +1,80 % bei einem Aktienkurs von 8,500 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ENGENE HOLDINGS INC finden Sie auf Wallstreet Online.